Journal of thrombosis and haemostasis : JTH
-
J. Thromb. Haemost. · May 2021
Multicenter StudyAge-adjusted D-dimer cut-off levels to rule out venous thromboembolism in patients with non-high pre-test probability: Clinical performance and cost-effectiveness analysis.
As aging was found to be associated with increased D-dimer levels, the question arose whether D-dimer measurement was useful in the diagnostic strategy of venous thromboembolism (VTE) in elderly patients. ⋯ The diagnostic strategy of VTE based on the age-adjusted cut-off level for D-dimer in patients over 50 years was found to be safe, with NPV above 99%, and cost-effective.
-
J. Thromb. Haemost. · Apr 2021
Multicenter StudyClinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study.
High incidence of asymptomatic venous thromboembolism (VTE) has been observed in severe COVID-19 patients, but the characteristics of symptomatic VTE in general COVID-19 patients have not been described. ⋯ There is an excess risk of VTE in hospitalized COVID-19 patients. This novel model can aid early identification of patients who are at high risk for VTE.
-
J. Thromb. Haemost. · Jul 2020
Multicenter StudyHigh incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.
Coagulopathy is a common abnormality in patients with COVID-19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe COVID-19 patients. ⋯ Our results suggest considering both systematic screening of VTE and early therapeutic anticoagulation in severe ICU COVID-19 patients.
-
J. Thromb. Haemost. · Dec 2019
Randomized Controlled Trial Multicenter Study Comparative StudyRandomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
JNJ-9375 is an antibody against exosite 1 on thrombin, inhibits substrate binding but not catalytic activity. ⋯ JNJ-9375 was safe but less effective than apixaban. This may reflect weak thrombin inhibition or inability of JNJ-9375 to attenuate the growth of thrombi that formed before drug administration.
-
J. Thromb. Haemost. · Oct 2019
Multicenter Study Comparative StudyAnticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
Parenteral anticoagulants and vitamin K antagonists (VKAs) have constituted the cornerstone of venous thromboembolism (VTE) treatment. Meanwhile, direct oral anticoagulants (DOACs) provide physicians with an alternative. The Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE observes real-world treatment practices. ⋯ AC treatment patterns vary by patient population, geographic region and site of VTE. Guidelines for AC therapy are not always adhered to.